Skip to main content

Clearance of neurotoxic proteins in proteinopathies: from clearance pathways to therapeutic targets

A thematic series in Translational Neurodegenetion

  1. Many neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, are characterised by the accumulation of misfolded protein deposits in the brain, leading to a progressive destabilisatio...

    Authors: Douglas M. Lopes, Sophie K. Llewellyn and Ian F. Harrison
    Citation: Translational Neurodegeneration 2022 11:19
  2. Accumulating α-synuclein (α-syn) aggregates in neurons and glial cells are the staples of many synucleinopathy disorders, such as Parkinson’s disease (PD). Since brain adenosine becomes greatly elevated in age...

    Authors: Elisabet Jakova, Mohamed Taha Moutaoufik, Jeremy S. Lee, Mohan Babu and Francisco S. Cayabyab
    Citation: Translational Neurodegeneration 2022 11:9
  3. Alzheimer’s disease (AD) is the most common cause of dementia, and is characterized by amyloid-β (Aβ) plaques and tauopathy. Reducing Aβ has been considered a major AD treatment strategy in pharmacological and...

    Authors: Mincheol Park, Gia Minh Hoang, Thien Nguyen, Eunkyung Lee, Hyun Jin Jung, Youngshik Choe, Moon Hwan Lee, Jae Youn Hwang, Jae Gwan Kim and Tae Kim
    Citation: Translational Neurodegeneration 2021 10:48
  4. Focused ultrasound (FUS)-mediated blood–brain barrier (BBB) opening has shown efficacy in removal of amyloid plaque and improvement of cognitive functions in preclinical studies, but this is rarely reported in...

    Authors: So Hee Park, Kyoungwon Baik, Seun Jeon, Won Seok Chang, Byoung Seok Ye and Jin Woo Chang
    Citation: Translational Neurodegeneration 2021 10:44